跳到正文
原文
Endpoints News 生物医药· ENDPOINTS·· 10 天前AI 评分35

PepGen 的寡核苷酸疗法在 DM1 中期试验中取得积极信号

PepGen's oligo succeeds in Phase 2; Ionis' and ImmunityBio's stocks sag

AI 导读

PepGen 的寡核苷酸疗法 PGN-EDODM1 在 DM1 的中期试验中显示出早期积极信号。Ionis 和 ImmunityBio 的股票下跌。

正文

Plus news about Co­herus On­col­o­gy, JW Ther­a­peu­tics and PsiThera.

Pep­Gen’s pos­i­tive mid-stage re­sults in DM1: Pep­Gen said its oligonu­cleotide ther­a­py PGN-EDODM1 showed pos­i­tive ear­ly sig­nals …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news